Publicaciones (92) Publicaciones de ALFREDO RODRIGUEZ-ANTIGUEDAD ZARRANZ

2024

  1. Autoimmune inflammation triggers aberrant astrocytic calcium signaling to impair synaptic plasticity

    Brain, Behavior, and Immunity, Vol. 121, pp. 192-210

  2. Autoimmune-associated epilepsy in an outpatient epilepsy clinic: A retrospective study

    Neurology Perspectives, Vol. 4, Núm. 1

  3. Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management

    Therapeutic Advances in Neurological Disorders, Vol. 17

  4. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  5. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

  6. Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

    Neurologia, Vol. 39, Núm. 5, pp. 383-391

  7. Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology

    Journal of Alzheimer's disease : JAD, Vol. 102, Núm. 1, pp. 207-217

  8. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis

    Frontiers in Public Health, Vol. 12

  9. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I)

    Revista de neurologia, Vol. 79, Núm. 1, pp. 21-29

  10. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II)

    Revista de neurologia, Vol. 79, Núm. 2, pp. 51-66

2023

  1. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

    PharmacoEconomics - Open, Vol. 7, Núm. 3, pp. 431-441

  2. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  3. Planificación familiar en hombres y mujeres con esclerosis múltiple. Análisis del Registro Andaluz (2018-2022)

    Revista de neurologia, Vol. 76, Núm. 12, pp. 377-383

  4. Therapeutic effect of α7 nicotinic receptor activation after ischemic stroke in rats

    Journal of Cerebral Blood Flow and Metabolism, Vol. 43, Núm. 8, pp. 1301-1316

  5. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  6. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Assessing care-related regret among nurses specialized in multiple sclerosis: A psychometric analysis of a new assessment battery

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 8, Núm. 4

  2. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

  3. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  4. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

    Multiple Sclerosis and Related Disorders, Vol. 63